Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.

MLA

Alexander, John, et al. “Pathway-Based Signatures Predict Patient Outcome, Chemotherapy Benefit and Synthetic Lethal Dependencies in Invasive Lobular Breast Cancer.” British Journal of Cancer, vol. 130, no. 11, May 2024, pp. 1828–40. EBSCOhost, https://doi.org/10.1038/s41416-024-02679-7.

APA

Alexander, J., Schipper, K., Nash, S., Brough, R., Kemp, H., Iacovacci, J., Isacke, C., Natrajan, R., Sawyer, E., Lord, C. J., & Haider, S. (2024). Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer. British Journal of Cancer, 130(11), 1828–1840. https://doi.org/10.1038/s41416-024-02679-7

Chicago

Alexander, John, Koen Schipper, Sarah Nash, Rachel Brough, Harriet Kemp, Jacopo Iacovacci, Clare Isacke, et al. 2024. “Pathway-Based Signatures Predict Patient Outcome, Chemotherapy Benefit and Synthetic Lethal Dependencies in Invasive Lobular Breast Cancer.” British Journal of Cancer 130 (11): 1828–40. doi:10.1038/s41416-024-02679-7.